Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results tomorrow after market hours. Here’s what you need to know. Supernus Pharmaceuticals ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with ...

TONIT GHTHEY HOST THE DALLAS STARS. BUT IT WILL ALSO BE MIKE LANGE NIT.GH THE PENS HONORING THE LEGENDARY PLAY-BY-PLAY ANNOUNCER, WHO ANNOUNCED HIS RETIREMENT IN AUGU.ST LANGE HAD SPENT 46 YEARS ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset missed its primary endpoint in a phase 2b trial. SPN-820 failed to improve ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...

Cantor Fitzgerald last night downgraded Supernus (SUPN) to Neutral from Overweight with a price target of $36, down from $57. The firm cites the “disappointing” Phase 2b data from SPN-82 in ...

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment ...

The Viera Company and Viera Builders have announced new hires and promotions that are part of recent organizational changes.

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...